Mithra Pharmaceuticals SA/NV Announces the Last Patient Enrollment in the Pharmacodynamics & Pharmacokinetics Studies of the Zoreline® Implant 10.8 mg


Liège, Belgium 18 November 2015 – Regulated information:  Mithra Pharmaceuticals, leader in Women’s Health and cutting-edge technological company in the field of API slow-release drugs based on polymere (subcutaneous implants, biocompatible rings, hormonal IUD’s), announced today that it has enrolled the last patient required in the pharmacodynamics & pharmacokinetics studies of its Zoreline® subcutaneous implant 10.8 mg.

Read the press release